Speakers

Chris Williams

Principal Engineer • DeSci Applied Research

Chris is a seasoned professional with extensive experience in the life sciences industry, particularly in roles focused on bioprocess development and gene therapies. With a track record spanning over a decade, Chris has consistently demonstrated strategic and technical prowess in various organizations.

At Roche, Chris has held influential roles, making significant contributions to the advancement of in vivo gene therapies. As a Principal Engineer, he has been responsible for strategic and technical development of an AAV platform for gene therapies. His accomplishments include designing and commissioning a new development center for AAV vector production, leading innovative operations for downstream processing, and driving initiatives to reduce the cost of gene therapies while expanding access for rare disease patients.

Chris’s experience also includes roles at Genentech, where he showcased his expertise in purification development. As an Engineer and later a Senior Engineer, he led the development and manufacturing of antibody purification processes, played a pivotal role in Phase III clinical campaigns, conducted technology transfers, and implemented analytical techniques for process optimization.

His comprehensive skill set, spanning technical development, team leadership, technology transfer, and analytical characterization, has enabled him to make substantial contributions to the life sciences field. Chris’s dedication to innovation and his impact on product development and purification processes underscore his significance as a leader in the industry.

Also speaking

Lucy Ellerker-Jones

Founder • Opie Jones Foundation

Eduard Hergenreider

Product Manager • SAP

Dale Stibbs

Post-Doctoral Fellow • UCL

Event Info

Image

Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.
Image

2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.